Clinical applications and the effect of mexiletine on refractory epilepsies

H. Enoki, H. Hata, Iori Ohmori, S. Maniwa, H. Ohta, Katsuhiro Kobayashi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Twenty-four patients with refractory epilepsy were treated with mexiletine as an additional antiepileptic drug. As the initial responses, seizures were decreased by 50% or more in 7 (46.7%) of 15 patients with symptomatic partial epilepsy (SPE), in none of 7 with symptomatic generalized-epilepsy (SGE), and in 1 of 2 with undetermined epilepsy. Seizures increased in 3 patients (20.0%) with SPE, and in 3 (42.9%) with SGE. Concerning seizure types, mexiletine had significant effects on 1 of 2 patients with simple partial seizures, on 7 of 13 with complex partial seizures, on 1 of 5 with secondarily generalized seizures, and on 1 of 8 with tonic seizures. No patients with a myoclonic seizure or atypical absence improved. Exacerbation of the seizures was observed in 2 of 13 patients with complex partial seizures, in 1 of 5 with secondarily generalized seizures, in 3 of 8 with tonic seizures, and in 2 of 3 with myoclonic seizures. Partial seizures were controlled well, whereas generalized seizures sometimes worsened. EEG improved in 3 patients with SPE; decrease of focal spikes in 2 patients and disappearance of secondary generalization in 1. Follow-up for more than 3 months showed seizures to be lessened in 2 patients. Mexiletine is useful for the treatment of refractory epilepsies, especially SPE.

Original languageEnglish
Pages (from-to)29-34
Number of pages6
JournalNo To Hattatsu
Volume32
Issue number1
Publication statusPublished - 2000

Fingerprint

Mexiletine
Epilepsy
Seizures
Partial Epilepsy
Generalized Epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Clinical applications and the effect of mexiletine on refractory epilepsies. / Enoki, H.; Hata, H.; Ohmori, Iori; Maniwa, S.; Ohta, H.; Kobayashi, Katsuhiro.

In: No To Hattatsu, Vol. 32, No. 1, 2000, p. 29-34.

Research output: Contribution to journalArticle

Enoki, H. ; Hata, H. ; Ohmori, Iori ; Maniwa, S. ; Ohta, H. ; Kobayashi, Katsuhiro. / Clinical applications and the effect of mexiletine on refractory epilepsies. In: No To Hattatsu. 2000 ; Vol. 32, No. 1. pp. 29-34.
@article{96802152ead742ce97835cc1aac4c775,
title = "Clinical applications and the effect of mexiletine on refractory epilepsies",
abstract = "Twenty-four patients with refractory epilepsy were treated with mexiletine as an additional antiepileptic drug. As the initial responses, seizures were decreased by 50{\%} or more in 7 (46.7{\%}) of 15 patients with symptomatic partial epilepsy (SPE), in none of 7 with symptomatic generalized-epilepsy (SGE), and in 1 of 2 with undetermined epilepsy. Seizures increased in 3 patients (20.0{\%}) with SPE, and in 3 (42.9{\%}) with SGE. Concerning seizure types, mexiletine had significant effects on 1 of 2 patients with simple partial seizures, on 7 of 13 with complex partial seizures, on 1 of 5 with secondarily generalized seizures, and on 1 of 8 with tonic seizures. No patients with a myoclonic seizure or atypical absence improved. Exacerbation of the seizures was observed in 2 of 13 patients with complex partial seizures, in 1 of 5 with secondarily generalized seizures, in 3 of 8 with tonic seizures, and in 2 of 3 with myoclonic seizures. Partial seizures were controlled well, whereas generalized seizures sometimes worsened. EEG improved in 3 patients with SPE; decrease of focal spikes in 2 patients and disappearance of secondary generalization in 1. Follow-up for more than 3 months showed seizures to be lessened in 2 patients. Mexiletine is useful for the treatment of refractory epilepsies, especially SPE.",
author = "H. Enoki and H. Hata and Iori Ohmori and S. Maniwa and H. Ohta and Katsuhiro Kobayashi",
year = "2000",
language = "English",
volume = "32",
pages = "29--34",
journal = "No To Hattatsu",
issn = "0029-0831",
publisher = "Japanese Society of Child Neurology",
number = "1",

}

TY - JOUR

T1 - Clinical applications and the effect of mexiletine on refractory epilepsies

AU - Enoki, H.

AU - Hata, H.

AU - Ohmori, Iori

AU - Maniwa, S.

AU - Ohta, H.

AU - Kobayashi, Katsuhiro

PY - 2000

Y1 - 2000

N2 - Twenty-four patients with refractory epilepsy were treated with mexiletine as an additional antiepileptic drug. As the initial responses, seizures were decreased by 50% or more in 7 (46.7%) of 15 patients with symptomatic partial epilepsy (SPE), in none of 7 with symptomatic generalized-epilepsy (SGE), and in 1 of 2 with undetermined epilepsy. Seizures increased in 3 patients (20.0%) with SPE, and in 3 (42.9%) with SGE. Concerning seizure types, mexiletine had significant effects on 1 of 2 patients with simple partial seizures, on 7 of 13 with complex partial seizures, on 1 of 5 with secondarily generalized seizures, and on 1 of 8 with tonic seizures. No patients with a myoclonic seizure or atypical absence improved. Exacerbation of the seizures was observed in 2 of 13 patients with complex partial seizures, in 1 of 5 with secondarily generalized seizures, in 3 of 8 with tonic seizures, and in 2 of 3 with myoclonic seizures. Partial seizures were controlled well, whereas generalized seizures sometimes worsened. EEG improved in 3 patients with SPE; decrease of focal spikes in 2 patients and disappearance of secondary generalization in 1. Follow-up for more than 3 months showed seizures to be lessened in 2 patients. Mexiletine is useful for the treatment of refractory epilepsies, especially SPE.

AB - Twenty-four patients with refractory epilepsy were treated with mexiletine as an additional antiepileptic drug. As the initial responses, seizures were decreased by 50% or more in 7 (46.7%) of 15 patients with symptomatic partial epilepsy (SPE), in none of 7 with symptomatic generalized-epilepsy (SGE), and in 1 of 2 with undetermined epilepsy. Seizures increased in 3 patients (20.0%) with SPE, and in 3 (42.9%) with SGE. Concerning seizure types, mexiletine had significant effects on 1 of 2 patients with simple partial seizures, on 7 of 13 with complex partial seizures, on 1 of 5 with secondarily generalized seizures, and on 1 of 8 with tonic seizures. No patients with a myoclonic seizure or atypical absence improved. Exacerbation of the seizures was observed in 2 of 13 patients with complex partial seizures, in 1 of 5 with secondarily generalized seizures, in 3 of 8 with tonic seizures, and in 2 of 3 with myoclonic seizures. Partial seizures were controlled well, whereas generalized seizures sometimes worsened. EEG improved in 3 patients with SPE; decrease of focal spikes in 2 patients and disappearance of secondary generalization in 1. Follow-up for more than 3 months showed seizures to be lessened in 2 patients. Mexiletine is useful for the treatment of refractory epilepsies, especially SPE.

UR - http://www.scopus.com/inward/record.url?scp=0033970808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033970808&partnerID=8YFLogxK

M3 - Article

C2 - 10655748

AN - SCOPUS:0033970808

VL - 32

SP - 29

EP - 34

JO - No To Hattatsu

JF - No To Hattatsu

SN - 0029-0831

IS - 1

ER -